Enovis Corporation
NYSE:ENOVMedical - Devices
+$0.73 today
- Market cap
- $1.56B
- Beta
- 1.49
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$20.02
Volume 0.88M
Average 0.99M
ENOV Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Enovis CorporationNYSE: ENOV
Research & Development · Q1 FY2026 · quarter ended Apr 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $31.53M rose 10.5% year over year, behind the +27.9% change in trailing-twelve-month research & development. Sequentially, it rose 0.5% from the prior quarter. Over 3 fiscal years it compounded at +25.5% a year.
Context
- Research & development amounted to 5.4% of revenue in FY2025, up 1.0 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +10.5% toward the trailing-twelve-month pace of +27.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 120.33M USD
- Year-over-year change
- +31.8%
- 4-year CAGR
- +25.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 120.33M | +31.8% |
| FY2024 | 2024-12-31 | 91.3M | +21.2% |
| FY2023 | 2023-12-31 | 75.33M | +23.8% |
| FY2022 | 2022-12-31 | 60.83M | +23.9% |
| FY2021 | 2021-12-31 | 49.09M | — |
Research & Development vs competitors
How ENOV compares with its peers on the latest reported figures
- ENOV's LTM Apr 2026 research & development of $123.34M is the 2nd highest of the 16 companies compared; the peer median is $0.
- Its year-over-year change of +27.9% is the highest of 9, against a peer median of -3.2%.
- Research & development amounts to 5.4% of revenue for ENOV, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $123.8M | +10.0% | +4.7% | 2.6% | |
| LTM Apr 2026 | $123.34M | +27.9% | +25.5% | 5.4% | |
| LTM Jul 2026 | $76.1M | -13.3% | -0.9% | 2.0% | |
| LTM Jun 2026 | $19.2M | +14.3% | — | 0.7% | |
| LTM Jul 2026 | $16.56M | +15.4% | +6.3% | 1.4% | |
| LTM Jul 2026 | $5.1M | — | — | 0.6% | |
| LTM Mar 2026 | $4.6M | +7.0% | -4.3% | 1.2% | |
| LTM Mar 2026 | $382K | -91.0% | -35.3% | 0.4% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Jul 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | -100.0% | +6.2% | 0.0% | |
| LTM Feb 2026 | $0 | -100.0% | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Apr 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ENOV) | $0 | -3.2% | +1.9% | 0.0% | |
Competitors are the stored peer set for ENOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.43B | 1.56B | 1.71B | 2.11B | 2.25B |
| Cost of Revenue | 648.51M | 693.72M | 716.42M | 926.87M | 902.79M |
| Gross Profit | 777.68M | 869.38M | 990.78M | 1.18B | 1.35B |
| Gross Margin | 54.5% | 55.6% | 58.0% | 56.0% | 59.8% |
| Research & Development | 49.09M | 60.83M | 75.33M | 91.3M | 120.33M |
| Selling, General & Admin | 665.78M | 772.91M | 830.31M | 939.36M | 1.07B |
| Operating Expenses | 840.47M | 940.56M | 1.06B | 1.96B | 1.36B |
| Depreciation & Amortization | 262.92M | 219.71M | 217.11M | 284.8M | 294.38M |
| EBITDA | 170.25M | 241.69M | 169.73M | (481.03M) | (830.22M) |
| EBITDA Margin | 11.9% | 15.5% | 9.9% | -22.8% | -36.9% |
| Operating Income | (62.8M) | (71.18M) | (65.71M) | (775.72M) | (18.87M) |
| Operating Margin | -4.4% | -4.6% | -3.8% | -36.8% | -0.8% |
| Interest Income | 0 | 200K | 0 | 0 | 0 |
| Interest Expense | 29.11M | 24.95M | 19.75M | 57.1M | 34.82M |
| Other Income / Expenses | (58.98M) | 69.11M | (1.42M) | (47.21M) | (1.14B) |
| Income Before Tax | (121.78M) | (2.07M) | (67.13M) | (822.92M) | (1.16B) |
| Pre-Tax Margin | -8.5% | -0.1% | -3.9% | -39.0% | -51.6% |
| Income Tax Expense | (19.53M) | 36.12M | (13.29M) | 4.49M | 22.29M |
| Net Income | 71.66M | (13.29M) | (33.26M) | (825.49M) | (1.18B) |
| Net Margin | 5.0% | -0.9% | -1.9% | -39.2% | -52.7% |
| EPS (Basic) | (2.02) | (0.28) | (0.61) | (14.93) | (20.86) |
| EPS (Diluted) | (2.02) | (0.28) | (0.61) | (14.93) | (20.86) |
| Weighted Avg Shares | 51.14M | 54.07M | 54.53M | 55.28M | 56.79M |
| Weighted Avg Shares (Diluted) | 51.14M | 54.07M | 54.49M | 55.28M | 56.79M |
Enovis Corporation
NYSE:ENOV
Intrinsic Alpha fair value
Locked
Current Price
$27.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.